|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEP164 |
Gene summary for CEP164 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEP164 | Gene ID | 22897 |
| Gene name | centrosomal protein 164 | |
| Gene Alias | NPHP15 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UPV0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22897 | CEP164 | LZE4T | Human | Esophagus | ESCC | 9.64e-07 | 1.94e-01 | 0.0811 |
| 22897 | CEP164 | LZE7T | Human | Esophagus | ESCC | 2.06e-04 | 1.37e-01 | 0.0667 |
| 22897 | CEP164 | LZE24T | Human | Esophagus | ESCC | 3.48e-17 | 3.91e-01 | 0.0596 |
| 22897 | CEP164 | LZE21T | Human | Esophagus | ESCC | 2.18e-04 | 1.78e-01 | 0.0655 |
| 22897 | CEP164 | P1T-E | Human | Esophagus | ESCC | 1.37e-04 | 2.01e-01 | 0.0875 |
| 22897 | CEP164 | P2T-E | Human | Esophagus | ESCC | 3.66e-15 | 2.16e-01 | 0.1177 |
| 22897 | CEP164 | P4T-E | Human | Esophagus | ESCC | 3.37e-20 | 3.22e-01 | 0.1323 |
| 22897 | CEP164 | P5T-E | Human | Esophagus | ESCC | 1.54e-16 | 2.20e-01 | 0.1327 |
| 22897 | CEP164 | P8T-E | Human | Esophagus | ESCC | 9.89e-09 | 1.15e-02 | 0.0889 |
| 22897 | CEP164 | P9T-E | Human | Esophagus | ESCC | 2.02e-17 | 1.89e-01 | 0.1131 |
| 22897 | CEP164 | P10T-E | Human | Esophagus | ESCC | 4.62e-14 | 1.48e-01 | 0.116 |
| 22897 | CEP164 | P11T-E | Human | Esophagus | ESCC | 7.18e-11 | 2.59e-01 | 0.1426 |
| 22897 | CEP164 | P12T-E | Human | Esophagus | ESCC | 1.33e-09 | 2.01e-01 | 0.1122 |
| 22897 | CEP164 | P15T-E | Human | Esophagus | ESCC | 4.86e-13 | 1.10e-01 | 0.1149 |
| 22897 | CEP164 | P16T-E | Human | Esophagus | ESCC | 7.55e-19 | 2.77e-01 | 0.1153 |
| 22897 | CEP164 | P17T-E | Human | Esophagus | ESCC | 1.94e-04 | 1.93e-01 | 0.1278 |
| 22897 | CEP164 | P20T-E | Human | Esophagus | ESCC | 1.40e-13 | 2.20e-01 | 0.1124 |
| 22897 | CEP164 | P21T-E | Human | Esophagus | ESCC | 2.95e-20 | 4.19e-01 | 0.1617 |
| 22897 | CEP164 | P22T-E | Human | Esophagus | ESCC | 1.12e-16 | 2.22e-01 | 0.1236 |
| 22897 | CEP164 | P23T-E | Human | Esophagus | ESCC | 1.70e-11 | 1.02e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEP164 | SNV | Missense_Mutation | c.2373N>G | p.Ser791Arg | p.S791R | Q9UPV0 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR | |
| CEP164 | SNV | Missense_Mutation | c.407C>T | p.Ser136Leu | p.S136L | Q9UPV0 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CEP164 | SNV | Missense_Mutation | c.3368N>G | p.Ser1123Cys | p.S1123C | Q9UPV0 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CEP164 | insertion | Nonsense_Mutation | novel | c.2129_2130insCCTGTAATCTCAGTGCTTTGGGAGGCT | p.Glu710delinsAspLeuTerSerGlnCysPheGlyArgLeu | p.E710delinsDL*SQCFGRL | Q9UPV0 | protein_coding | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CEP164 | insertion | Frame_Shift_Ins | novel | c.157_158insCATTGATGGAGAGAAAAGACAAA | p.Gly53AlafsTer52 | p.G53Afs*52 | Q9UPV0 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| CEP164 | insertion | Nonsense_Mutation | novel | c.1134_1135insCTTCCTTTCTAACATGGTCTGTTGCTCCCTAGG | p.Gly378_Ser379insLeuProPheTerHisGlyLeuLeuLeuProArg | p.G378_S379insLPF*HGLLLPR | Q9UPV0 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| CEP164 | deletion | Frame_Shift_Del | novel | c.1212delN | p.Lys406SerfsTer41 | p.K406Sfs*41 | Q9UPV0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CEP164 | SNV | Missense_Mutation | novel | c.881N>T | p.Ser294Ile | p.S294I | Q9UPV0 | protein_coding | deleterious(0) | possibly_damaging(0.62) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CEP164 | SNV | Missense_Mutation | novel | c.2794N>A | p.Glu932Lys | p.E932K | Q9UPV0 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CEP164 | SNV | Missense_Mutation | rs758393882 | c.3664N>A | p.Asp1222Asn | p.D1222N | Q9UPV0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |